| Total N = 57 | ME n = 29 | ME w/o LNB n = 22 | NIMM n = 22 | ||||
---|---|---|---|---|---|---|---|---|
p-value | r-value | p-value | r-value | p-value | r-value | p-value | r-value | |
CSF CXCL13 levels vs. Routine CSF Parameters: | ||||||||
 Cell Count |  < 0.0001 | 0.69 | 0.002 | 0.55 |  < 0.001 | 0.69 | 0.004 | 0.59 |
 QAlb |  < 0.0001 | 0.54 | 0.039 | 0.39 | 0.05 | 0.42 | 0.048 | 0.43 |
 CSF % IgG | 0.83 | −0.03 | 0.11 | −0.30 | 0.27 | −0.25 | 0.23 | 0.27 |
CSF CXCL13 levels vs Immune Cell Phenotypes (%): | ||||||||
 CD19+  | 0.004 | 0.38 | 0.57 | 0.11 | 0.64 | 0.10 | 0.005 | 0.57 |
 CD3+CD4 | 0.57 | −0.08 | 0.79 | −0.05 | 0.89 | 0.03 | 0.90 | 0.03 |
 → CXCR5+CD4 |  < 0.0001 | 0.59 | 0.003 | 0.54 | 0.001 | 0.65 | 0.043 | 0.44 |
 CD3 +CD8 | 0.06 | −0.25 | 0.36 | −0.18 | 0.40 | −0.19 | 0.09 | −0.37 |
 → CXCR5+CD8 | 0.012 | 0.33 | 0.50 | 0.13 | 0.35 | 0.21 | 0.32 | 0.23 |
 CD19+vs. CXCR5+CD4 (%) |  < 0.001 | 0.44 | 0.16 | 0.27 | 0.94 | −0.02 | 0.030 | 0.46 |
CSF CXCL13 vs. immune cell phenotypes (cells/µl): | ||||||||
 CD19+ |  < 0.0001 | 0.63 | 0.06 | 0.36 | 0.035 | 0.45 |  < 0.001 | 0.69 |
 CD3+CD4 |  < 0.0001 | 0.64 | 0.025 | 0.42 | 0.007 | 0.56 | 0.005 | 0.58 |
 → CXCR5+CD4 |  < 0.0001 | 0.70 | 0.001 | 0.58 |  < 0.001 | 0.68 |  < 0.01 | 0.60 |
 CD3+CD8 |  < 0.0001 | 0.61 | 0.044 | 0.38 | 0.021 | 0.49 | 0.040 | 0.44 |
 → CXCR5+CD8 |  < 0.0001 | 0.62 | 0.048 | 0.37 | 0.021 | 0.49 | 0.028 | 0.47 |
 | Total N = 49 | ME n = 26 | ME w/o LNB n = 21 | NIMM n = 19 | ||||
---|---|---|---|---|---|---|---|---|
p-value | r-value | p-value | r-value | p-value | r-value | p-value | r-value | |
CSF CXCL13 vs. CSF/PB ratio of immune cell phenotypes (%) | ||||||||
 CSF/PB ratio CD19+ | 0.10 | 0.24 | 0.63 | 0.09 | 0.92 | −0.02 | 0.039 | 0.48 |
 CSF/PB ratio CXCR5+CD4 | 0.001 | 0.45 | 0.005 | 0.50 | 0.010 | 0.55 | 0.18 | 0.32 |
 CSF/PB ratio CXCR5+CD8 | 0.17 | 0.20 | 0.99 | −0.00 | 0.65 | −0.10 | 0.29 | 0.25 |